Evidence map›Paper›PMID 35549935›Full record

ArticleInquiry : a journal of medical care organization, provision and financing

Cost-Effectiveness Threshold for Healthcare: Justification and Quantification.

Moshe Yanovskiy, Ori N Levy, Yair Y Shaki, Avi Zigdon, Yehoshua Socol

Abstract read
In one paragraph

Article in Inquiry : a journal of medical care organization, provision and financing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Are Lockdowns Effective in Managing Pandemics?International journal of environmental research and public health · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Moshe YanovskiyDepartment of Industrial Engineering, 42730Jerusalem College of Technology, Jerusalem, Israel.ORCID 0000-0002-7014-0522
Ori N LevyDepartment of Industrial Engineering, 42730Jerusalem College of Technology, Jerusalem, Israel.
Yair Y ShakiDepartment of Industrial Engineering, 42730Jerusalem College of Technology, Jerusalem, Israel.
Avi ZigdonDisaster Research Center, IL, 42732Ariel University, Ariel, Israel.ORCID 0000-0003-1849-7206
Yehoshua SocolDepartment of Electrical and Electronics Engineering, 42730Jerusalem College of Technology, Jerusalem, Israel.ORCID 0000-0003-4167-248X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Every public health expenditure, including the one that saves lives or extends life expectancy of particular persons (target population), bears a cost. Although cost-effectiveness analysis (CEA) is routinely performed in health policy, ethical justification of CEA is rarely discussed. Also, there is neither consensus value nor even consensus method for determining cost-effectiveness threshold (CET) for life-extending measures. In this study, we performed ethical analysis of CEA by policy impact assessment based on connection of health and wealth (poorer people have statistically shorter life expectancies) and concluded that CEA is not only a practical but also an ethical necessity. To quantify CET, we used three independent methods: (1) literature survey of analyzing salaries in risky occupations, (2) utilizing Prospect Theory suggesting that people value their lives in monetary terms twice more than their lifetime earnings, and (3) literature survey of the U.S. current legal practice. To the best of our knowledge, nobody applied method (2) to determine CET. The three methods yielded rather similar results with CET about 1.0 ± 0.4 gross domestic product per capita (GDPpc) per quality-adjusted life-year. Therefore, a sum of not higher than 140% GDPpc is statistically sufficient to "purchase" an additional year of life-or, alternatively, to "rob" one year of life if taken away. Therefore, 140% GDP per capita per quality-adjusted life-year should be considered as the upper limit of prudent and ethically justified expenditure on life extension programs.

Indexed as

Delivery of Health CareHealth ExpendituresCost-Benefit AnalysisHealth FacilitiesHumansQuality-Adjusted Life Yearscost-benefit analysisethicshealth policyrisk managementwillingness to pay

Identifiers

PMID35549935
PMCPMC9109272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.